LAVA Therapeutics’ (LVTX) Market Perform Rating Reiterated at Leerink Partners

Leerink Partners reiterated their market perform rating on shares of LAVA Therapeutics (NASDAQ:LVTX) in a research note published on Thursday, MarketBeat.com reports. They currently have a $2.00 price objective on the stock, down from their prior price objective of $11.00.

Other equities research analysts have also issued reports about the stock. JMP Securities reiterated a “market perform” rating and issued a $6.00 price target on shares of LAVA Therapeutics in a research note on Wednesday. Citizens Jmp downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.67.

LAVA Therapeutics Price Performance

LVTX stock opened at $1.11 on Thursday. The stock has a market capitalization of $28.14 million, a P/E ratio of -1.08 and a beta of 0.43. LAVA Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $6.47. The business has a 50-day moving average of $1.69 and a 200-day moving average of $1.83.

Institutional Trading of LAVA Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new position in shares of LAVA Therapeutics during the 3rd quarter worth about $32,000. XTX Topco Ltd bought a new position in LAVA Therapeutics during the second quarter worth about $55,000. Finally, Pathway Financial Advisors LLC increased its position in LAVA Therapeutics by 70.8% during the third quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock worth $170,000 after buying an additional 42,500 shares during the last quarter.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.